Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 701 shares of the company’s stock after acquiring an additional 45 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Medpace were worth $233,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. The Manufacturers Life Insurance Company raised its position in shares of Medpace by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,129 shares of the company’s stock valued at $8,702,000 after purchasing an additional 94 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Medpace in the 2nd quarter valued at about $747,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Medpace by 95.7% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company’s stock valued at $93,000 after purchasing an additional 110 shares in the last quarter. Truist Financial Corp grew its stake in Medpace by 21.2% in the second quarter. Truist Financial Corp now owns 3,700 shares of the company’s stock worth $1,524,000 after purchasing an additional 648 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in shares of Medpace by 2.3% during the 2nd quarter. Cetera Investment Advisers now owns 11,757 shares of the company’s stock valued at $4,842,000 after acquiring an additional 263 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP opened at $343.02 on Thursday. The stock’s fifty day moving average is $341.77 and its 200-day moving average is $353.45. Medpace Holdings, Inc. has a one year low of $286.76 and a one year high of $459.77. The company has a market capitalization of $10.66 billion, a PE ratio of 30.04, a P/E/G ratio of 1.77 and a beta of 1.36.

Analyst Ratings Changes

MEDP has been the subject of a number of research reports. TD Cowen decreased their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird upped their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday. Redburn Atlantic initiated coverage on Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 price target on the stock. William Blair restated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Finally, Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.